Across TCGA pan-cancer cohorts, STK32B mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated STK32B data layer compared with 24 for mass-spec protein and 4 for mutation status.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher STK32B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated STK32B expression acts as an unfavorable survival marker.
CCRCC are the cancer types where STK32B mass-spec protein most reproducibly stratifies survival.